| 1. |
|
Anthrax: The Investigation of a Deadly
Outbreak. Nature Medicine.2000 Mar;6:245. |
| 2. |
|
Furmanski M., Anthrax. New England Journal
of Medicine. 2000 Jan 6;342:61-2. |
| 3. |
|
Danzig R, et al. Why should we be concerned
about biological warfare? JAMA. 1997 Aug 6;278:431-432. |
| 4. |
|
Christopher GW, et al. Biological Warfare:
a historical perspective. JAMA. 1997;278:412-417. |
| 5. |
|
Osmon DR., Antimicrobial prophylaxis
in adults. Mayo Clinic Proceedings. 2000 Jan;75:98-109. |
| 6. |
|
Inglesby TV, Henderson DA, Bartlett JG,
Ascher MS, Eitzen E, Friedlander AM, et al. Anthrax as a biological
weapon: medical and public health management. JAMA. 1999;281:1735-1745.
|
| 7. |
|
Dixon TC, Meselson M, Guillemin J, Hanna
PC. Anthrax. New England Journal of Medicine. 1999 Sep 9;341:815-26.
|
| 8. |
|
http://www.cdc.gov/ncidod/dbmd/diseaseinfo/anthrax_g.htm
|
| 9. |
|
http://www.anthrax.osd.mil/oldavip/anth.htm
|
| 10. |
|
http://health.yahoo.com/health/Diseases_and_Conditions/Disease_Feed_Data/Anthrax/ |
| 11. |
|
http://www2.adam.com/ |
| 12. |
|
Nass M. Anthrax Vaccine: Model Response
to the Biological Warfare Threat. Infectious Disease Clinics
of North America. 1999 March:187-208. |
| 13. |
|
McBride BW, Mogg A, Telfer JL, Lever
MS, Miller J, Turnbull PCB and Baille L. Protective efficacy
of a recombinant protective antigen against Bacillus anthracis challenge
and assessment of immunological markers. Vaccine. 1998:16:
810-817. |
| 14. |
|
Ivins BE, Pitt MLM, Fellows PF, Farchaus
JW, Benner GE, Waag DM, Little SF, Anderson GW Jr, Gibbs PH and
Friedlander AM. Comparative efficacy of experimental anthrax
vaccine candidates against inhalation anthrax in rhesus macaques.
Vaccine. 1998:16:1141-1148. |
| 15. |
|
Gu Mi-Li, Leppla SH, Klinman DM. Protection
against anthrax toxin by vaccination with a DNA plasmid encoding
anthrax protective antigen. Vaccine. 1999:17:340-344. |
| 16. |
|
Shafazand S, Doyle R, Ruoss S, Weinacker
A, Raffin TA. Inhalation Anthrax: epidemiology, diagnosis,
and management. Chest. November 1999:116:1369-1376. |
| 17. |
|
Demicheli V, Rivetti D, Deeks JJ, Jefferson
T and Pratt M. The effectiveness and safety of vaccines
against human anthrax: a systematic review. Vaccine 1998:16:880-884.
|
| 18. |
|
Duesbery NS and Vande Woude GF.
Anthrax toxins. Cellular and Molecular Life Sciences. 1999:55:1599-1609.
|
| 19. |
|
Ivins BE, Fellows PF, Pitt MLM, Estep
JE, Welkos SL, Worsham PL and Friedlander AM. Efficacy of a standard
human anthrax vaccine against Bacillus anthracis aerosol spore challenge
in rhesus monkeys. Salisbury Medical Bulletin, Special Suppl. no.
87, 1996: 125-126. |
| 20. |
|
Goletz TJ, Klimpel KR, Leppla SH, Keith
JM; Berzofsky JA. Delivery of antigens to the MHC class I pathway
using bacterial toxins. Human Immunology. May 1997:54(2):129-36. |
| 21. |
|
Smith H and Kreppie J. Observations on
experimental anthrax: demonstration of a specific lethal factor
produced in vivo by Bacillus Anthracis. Nature 173: 869-870. |
